Last reviewed · How we verify
NCT05601037: LVARCT
LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema
NA trial testing Axilla dissection + Lymphovenous anastomosis in Lymphedema, Breast Cancer in 80 participants. Currently enrolling.
27 December 2025
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 30 June 2021 |
| Primary completion | 27 December 2025 |
| Estimated completion | 27 December 2026 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Axilla dissection + Lymphovenous anastomosis
Conditions studied
- Lymphedema, Breast Cancer — all drugs for Lymphedema, Breast Cancer →
Sponsor
University Hospital, Ghent
Who can join
Adults 18 to 99, female only, with Lymphedema, Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymphedema is defined as a chronic condition, caused by lymphostasis. A major part in the Western world consists of iatrogenic lymphedema caused by surgery to the lymph nodes of the axilla or groin. Prophylactic lymphovenous anastomosis (LVA) could be beneficial in the prevention of lymphedema of the extremities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05601037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphedema, Breast Cancer
Currently open trials in the same condition.
- NCT07257679 — Gentle Touch for Post-Mastectomy Lymphedema · Phase 4 · recruiting
- NCT06302361 — Lymphovenous Anastomosis for Breast Cancer Lymphedema · NA · active not recruiting
- NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
- NCT05366699 — LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy · NA · recruiting
- NCT04888975 — A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients Wit · NA · recruiting
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05601037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing